GRAIL Director Steven Mizell Acquires 268 Shares Through Deferred Stock Unit Award

Director Compensation Structure at GRAIL Through Equity Awards

GRAIL, Inc. operates within the highly specialized segment of early cancer detection through liquid biopsy and genomic analysis technologies. The company compensates its board members in part through equity awards as an alternative to cash-based director fees, aligning leadership incentives with shareholder interests. The deferred stock unit program allows directors to receive company shares based on the fair market value of foregone cash compensation, calculated using the closing stock price on the date of grant.

The award issued to Mizell represents director compensation tied to his ongoing service on the GRAIL board. By converting $19,945.21 of cash fees into 268 common shares at the July 15, 2026 closing price of $74.36 per share, GRAIL continues to emphasize equity participation as a core element of its governance and board retention strategy. This approach preserves company cash while fostering direct ownership alignment between directors and shareholders.

Details of the July 2026 Stock Acquisition

The transaction occurred on July 15, 2026, when Steven Mizell, identified as a director of GRAIL, acquired 268 shares of the company's common stock through the deferred stock unit program established under the company's 2024 Equity Incentive Plan. The shares were issued in lieu of director fees that would otherwise have been paid in cash. The valuation of $74.36 per share reflects the official closing price of GRAIL common stock on the date of grant, establishing the conversion rate between cash compensation and equity awards.

The award vested immediately upon the grant date, meaning Mizell gained full ownership rights to the 268 shares without a waiting period. This immediate vesting structure for director compensation awards is consistent with GRAIL's approach to ensuring directors hold unrestricted beneficial ownership in the company. The transaction was filed on July 16, 2026, one business day after the award date, consistent with standard regulatory reporting timelines for Form 4 disclosures related to equity acquisitions by company insiders.

Mizell's Growing Stake in GRAIL Common Stock

Following the acquisition of 268 shares, Steven Mizell's total beneficial ownership of GRAIL common stock reached 42,830 shares held in direct form. This aggregate ownership position reflects his accumulated equity stakes from prior director compensation awards and potential previous open market purchases or grants. The absolute number of shares beneficially owned by a director can serve as an indicator of their long-term commitment and confidence in the company's strategic direction and business prospects.

Mizell's direct ownership of 42,830 shares places him among GRAIL's insiders with measurable equity participation. While the magnitude of his holdings relative to total company capitalization was not disclosed in this report, the continued receipt of equity awards and maintenance of a growing direct equity position suggest Mizell intends to retain his stake in the company. Directors with substantial ownership often benefit directly from company performance and operational success, creating a natural alignment with broader shareholder interests.

Regulatory Disclosure and Insider Trading Compliance

The report was filed with the Securities and Exchange Commission on July 16, 2026, as a Form 4 statement of changes in beneficial ownership. This disclosure requirement applies to directors, officers, and other insiders under Section 16(a) of the Securities Exchange Act of 1934. Form 4 filings provide transparency regarding transactions in company securities by individuals with potential access to material nonpublic information, enabling investors to monitor insider trading patterns and assess potential conflicts of interest or signaling effects.

The filing indicates that the transaction was not executed pursuant to a Rule 10b5-1 trading plan, meaning it was not part of a pre-arranged, non-discretionary securities trading arrangement designed to comply with insider trading rules. This distinction is relevant because Rule 10b5-1 plans allow insiders to establish predetermined trading schedules when no material nonpublic information is known, providing legal certainty around timing and execution. The absence of such a plan designation here suggests the award was issued as part of the routine director compensation cycle rather than pursuant to a structured equity trading program.

GRAIL's Business Model and Insider Equity Participation

GRAIL, Inc. develops and commercializes blood-based cancer detection tests designed to identify cancer early, often before symptoms appear. The company operates in the broader oncology diagnostics market, competing with other molecular diagnostics providers and early detection platforms. GRAIL's technology relies on genomic sequencing and machine learning to identify cancer-associated DNA signals in circulating cell-free DNA found in blood samples, positioning it as a leader in the liquid biopsy segment of the diagnostics industry.

Director equity awards like those granted to Mizell reflect GRAIL's strategy of maintaining tight alignment between board governance and shareholder value creation. By compensating directors partly in company stock, GRAIL ensures its leadership has direct financial exposure to operational results, product development success, and market adoption of its cancer detection platform. This equity-based approach is particularly relevant in life sciences and diagnostics companies, where clinical validation, regulatory approvals, and commercial scaling significantly influence long-term shareholder returns.

Historical Context of Director Stock Compensation at GRAIL

The award issued to Mizell operates under GRAIL's 2024 Equity Incentive Plan, which governs the grant of equity awards to directors, officers, and employees. The plan framework established in 2024 provides the legal and administrative structure for issuing stock, stock options, restricted stock units, and deferred stock units to eligible participants. By consolidating equity award programs under a single plan, GRAIL maintains streamlined governance and reporting while preserving flexibility in structuring director compensation packages.

Director compensation programs that emphasize equity participation have become increasingly common across publicly traded companies, particularly in technology-driven and life sciences sectors. GRAIL's deferred stock unit approach allows the company to offer competitive director compensation without requiring significant cash outflows. The immediate vesting structure for director awards, as applied to Mizell's grant, ensures that board members can access their equity stake without restrictive conditions that might delay or inhibit their ability to hold or liquidate shares according to their personal investment preferences.

Valuation and Market Context for the Award

The $74.36 closing price on July 15, 2026, established the valuation basis for converting Mizell's director fees into equity. This per-share price represents the market's assessment of GRAIL's value at that specific point in time, reflecting investor sentiment regarding the company's cancer diagnostics platform, revenue growth, clinical trial outcomes, and competitive positioning. The use of the actual closing price ensures the equity award reflects current market conditions rather than historical or hypothetical valuations.

The implied value of the award ($19,945.21) represents a meaningful component of total director compensation, demonstrating GRAIL's commitment to equity-based incentive structures. By issuing 268 shares in place of cash fees, GRAIL preserved approximately $19,945 in liquid capital that might otherwise have been distributed to Mizell. This capital retention can support operational investments, research and development initiatives, or strategic partnerships aligned with GRAIL's cancer detection and commercialization objectives.

Insider Ownership Transparency and Investor Monitoring

The disclosure of Mizell's acquisition of 268 shares contributes to the broader body of information available to GRAIL shareholders and the investment community regarding insider trading patterns and director confidence signals. Investors often analyze patterns of insider transactions to assess whether company leadership is buying (signaling optimism) or selling (signaling caution or portfolio rebalancing). Director awards received in lieu of cash compensation are distinguished from open market purchases, but they nevertheless represent a form of insider capital allocation and confidence in the company.

The 42,830-share beneficial ownership position disclosed in this report establishes a public record of Mizell's equity stake, enabling shareholders to evaluate the magnitude of director alignment with company performance. Investors reviewing insider ownership data may use such information to assess whether board members hold significant financial exposure to the company's stock price, strategic decisions, and operational outcomes. The continued accumulation of shares through director compensation awards suggests Mizell intends to maintain and grow his ownership stake over time.

Regulatory Implications and Future Insider Reporting

As a director of a NASDAQ-listed company, Steven Mizell remains subject to Section 16 reporting requirements, obligating him to disclose changes in beneficial ownership within two business days of the transaction date. His continued participation in GRAIL's equity compensation programs means future director awards will similarly be disclosed through Form 4 filings, providing ongoing transparency into insider equity transactions. The two-day reporting window supports the SEC's goal of enabling timely public disclosure of insider trading activity and maintaining confidence in market integrity.

The filing also documents the signatory authority and legal representation used in submitting the Form 4 report. Donald Lang, serving as attorney-in-fact for Steven Mizell, executed the filing on July 16, 2026, on behalf of the reporting person. This arrangement is common where insiders delegate the mechanics of regulatory compliance to legal counsel or corporate administrators. The use of an attorney-in-fact does not alter the legal responsibility or accuracy obligations that apply to the underlying transaction disclosure or the beneficial ownership statements contained in the report.